Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
Crossref DOI link: https://doi.org/10.1038/s41408-020-0281-x
Published Online: 2020-01-28
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ferrara, Felicetto
Text and Data Mining valid from 2020-01-28
Version of Record valid from 2020-01-28
Article History
Received: 3 December 2019
Revised: 6 January 2020
Accepted: 14 January 2020
First Online: 28 January 2020
Conflict of interest
: The author declares that he has no conflict of interest.